CCL20 stimulates proinflammatory mediator synthesis in human fibroblast-like synoviocytes through a MAP kinase-dependent process with transcriptional and posttranscriptional control

Journal of Rheumatology

Volumn 38, Issue 9, 2011, Pages 1858-1865

  Alaaeddine, Nada ^a   Hilal, George ^a   Baddoura, Raffic ^a   Antoniou, John ^b   Di Battista, John A ^c  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Arthritis; CCL20; Fibroblast like synoviocytes; Map kinase

Indexed keywords

CELL EXTRACT; CHEMOKINE RECEPTOR CCR6; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C BETAII; RECOMBINANT CCL20 PROTEIN; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT PROTEIN; RENILLA LUCIFERIN 2 MONOOXYGENASE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARTILAGE DEGENERATION; CCL20 GENE; CHEMOKINE RECEPTOR CCR6 GENE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST LIKE SYNOVIOCYTE; GENE; GENE CONSTRUCT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEDIATOR RELEASE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CHEMOKINE CCL20; FIBROBLASTS; HUMANS; INFLAMMATION MEDIATORS; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; OSTEOARTHRITIS; PROTEIN BIOSYNTHESIS; RECEPTORS, CCR6; SYNOVITIS; TRANSCRIPTION, GENETIC; YOUNG ADULT;

EID: 80052324543     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110049     Document Type: Article

References (33)

1. Majithia V, Geraci SA. Rheumatoid arthritis: Diagnosis and management. Am J Med 2007;120:936-9.
2. Lars K, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
3. Tak PP. Examination of the synovium and synovial fluid. Firestein GS, Panayi G, Wollheim F, editors. Rheumatoid arthritis. 2nd ed. New York: Oxford University Press; 2006:215-29.
4. Kraan MC, Haringman JJ, Weedon H, Barg, EC, Smith MD, Ahern MJ, et al. T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004;63:483-8. (Pubitemid 38530189)
5. Jin T, Xu X, Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine 2008;44:1-8.
6. Miossec P. Dynamic interactions between T cells and dendritic cells and their derived cytokines/chemokines in the rheumatoid synovium. Arthritis Res Ther 2008;10 Suppl 1:S2.
7. Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001;44:2750-60. (Pubitemid 34016194)
8. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001;78:57-110. (Pubitemid 32566018)
9. Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol 2009;36:2397-402.
10. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003;14:409-26. (Pubitemid 37099454)
11. Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 2008;275:4448-55.
12. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
13. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
14. Alaaeddine N, Di Battista JA, Pelletier JP, Kiansa K, Cloutier JM, Martel-Pelletier J. Differential effects of IL-8, LIF (pro-inflammatory) and IL-11 (anti-inflammatory) on TNF-alpha-induced PGE(2) release and on signalling pathways in human OA synovial fibroblasts. Cytokine 1999;11:1020-30. (Pubitemid 30045341)
15. Faour WH, Alaaeddine N, Mancini A, He QW, Jovanovic D, Di Battista JA. Early growth response factor-1 mediates prostaglandin E2-dependent transcriptional suppression of cytokine-induced tumour necrosis factor-α gene expression in human macrophages and rheumatoid-arthritis affected synovial fibroblasts. J Biol Chem 2005;280:9536-46. (Pubitemid 40409649)
16. Zhai B, Yang H, Mancini A, He QW, Antoniou J, Di Battista JA. Leukotriene B4 BLT receptor signalling regulates the level and stability of cyclooxygenase-2 (Cox-2) mRNA through restricted activation of Ras/c-Raf/ERK/p42 auf1 pathway. J Biol Chem 2010;285:23568-80.
17. Soberman RJ, Christmas P. The organization and consequences of eicosanoid signaling. J Clin Invest 2003;111:1107-13. (Pubitemid 36519924)
18. Faour WH, He Y, de Ladurantaye M, He W, Quintero M, Mancini A, et al. Prostaglandin E2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1β-treated human synovial fibroblasts. J Biol Chem 2001;276:31720-31.
19. Jenkins JK, Hardy KJ, McMurray RW. The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci 2002;323:171-80. (Pubitemid 34651586)
20. Smith JB, Haynes MK. Rheumatoid arthritis - a molecular understanding. Ann Intern Med 2002;136:908-22. (Pubitemid 34625703)
21. Buckley C, Pilling D, Lorda JM, Akbarb AN, Scheel-Toellnera D, Salmona M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2000;22:199-204. (Pubitemid 32673659)
22. Flavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD. Fibroblasts as novel therapeutic targets in chronic inflammation. Br J Pharmacol 2008;153:S241-6. (Pubitemid 351340977)
23. Nanki T, Takada K, Komano Y, Morio T, Kanegane H, Nakajima A, et al. Chemokine receptor expression and functional effects of chemokines on B cells. Implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 2009;11:R149.
24. Katschke KJ Jr, Rottman JB, Ruth JH, Qin S, Wu L, LaRosa G, et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001;44:1022-32. (Pubitemid 32433606)
25. Lisignoli G, Piacentini A, Cristino S, Grassi F, Cavallo C, Cattini L, et al. CCL20 chemokine induces both osteoblast proliferation and osteoclast differentiation: Increased levels of CCL20 are expressed in subchondral bone tissue of rheumatoid arthritis patients. J Cell Physiol 2007;210:798-806. (Pubitemid 46185049)
26. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3 alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001;167:6015-20. (Pubitemid 33062800)
27. Okamoto H, Hoshi D, Kiire A, Yamanaka H, Kamatani N. Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets 2008;7:53-66. (Pubitemid 351663646)
28. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 2001;19:617-35. (Pubitemid 33041643)
29. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-5.
30. Sugimoto Y, Naruyima S. Prostaglandin E receptors. J Biol Chem 2007;282:11613-7. (Pubitemid 47100657)
31. Mancini A. Prostaglandin E2: a central mediator of cytokine cell signaling through post-transcriptional and translational regulatory mechanisms in human synovial fibroblasts (HSF) [thesis]. Montreal: Department of Anatomy and Cell Biology, McGill University; 2005.
32. Gerarduzzi C. Characterizing the activating and attenuating signal scaffolding units of the PGE2-EP receptor system in normal and arthritic human synovial fibroblasts [thesis]. Montreal: Department of Experimental Medicine, McGill University; 2010.
33. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004;15:280-94. (Pubitemid 39423287)